The Novozymes Report 2010 has been audited by PwC. As part of its work, PwC has been the sustainability assurance provider and has based the assurance on the AA1000 Assurance Standard (2008).
The website contains the Novozymes Report (which, pursuant to section 149 of the Danish Financial Statements Act, is an extract of the company's annual report) and the financial statements of the parent company Novozymes A/S. Together these form the company’s annual report, which will be filed with the Danish Commerce and Companies Agency. The annual report is available at www.novozymes.com as a separate publication in Danish.
The audit covers financial, social, and environmental data, and PwC has audited as well as performed the assurance on all content in the Report, Outlook, Management, and Accounts sections of the Novozymes Report 2010. These are marked “Audited by PwC.” See also the statements in the report.
PwC has not audited the sections of the report found under the heading Supplementary reporting, which include our Communication on Progress with respect to the Global Compact, our report index based on the Global Reporting Initiative (GRI), and detailed sustainability data from our activities in Brazil, Canada, China, Denmark, India, Sweden, the UK, and the US.
The report has been produced in accordance with International Financial Reporting Standards (IFRS), the Danish Financial Statements Act, and the additional requirements of NASDAQ OMX Copenhagen A/S for the presentation of financial statements by listed companies. It has also been prepared as an element of Novozymes' reporting according to the GRI's G3 Guidelines for Sustainability Reporting.
The Novozymes Report 2010 contains forward-looking statements, including Novozymes’ financial outlook for 2011, which, by their very nature, are associated with risks and uncertainties that may cause actual results to differ materially from expectations.
The uncertainties may include unexpected developments in the international currency exchange and securities markets, market-driven price decreases for Novozymes’ products, and the introduction of competing products in Novozymes’ core areas. See Risk management.